Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 1 records in total 1
    records per page




    Early outcomes of tocilizumab in adults TRANS hospitalized with severe COVID19. An initial report from the Vall dHebron COVID19 prospective cohort study.

    Authors: Adrian Sanchez-Montalva; Julia Selares-Nadal; Juan Espinosa-Pereiro; Nuria Fernandez-Hidalgo; Santiago Perez-Hoyos; Fernando Salvador; Xavier Dura-Miralles; Marta Miarons; Andres Anton; Simeon Eremiev; Abiu Sempere-Gonzalez; Pau Bosch-Nicolau; Arnau Monforte-Pallares; Salvador Augustin; Julia Sampol; Alfredo Guillen-del-Castillo; Benito Almirante

    doi:10.1101/2020.05.07.20094599 Date: 2020-05-12 Source: medRxiv

    Background: Modulation of the immune system to prevent lung injury MESHD is being widely used against the new coronavirus disease MESHD (COVID19) despite the scarcity of evidence. Methods: We report preliminary results from the Vall dHebron prospective cohort study at Vall dHebron University Hospital, in Barcelona (Spain), including all consecutive patients who had a confirmed infection TRANS infection with the severe HP infection with the severe MESHD acute respiratory syndrome MESHD coronavirus2 (SARSCoV2) and who were treated with tocilizumab until March 25th. The primary endpoint was mortality at 7 days after tocilizumab administration. Secondary endpoints were admission to the intensive care unit, development of ARDS MESHD and respiratory insufficiency HP respiratory insufficiency MESHD among others. Results: 82 patients with COVID19 received at least one dose of tocilizumab. The mean (SD) age TRANS was 59.1 (19.8) years, 63% were male TRANS, 22% were of non Spanish ancestry, and the median (IQR) ageadjusted Charlson index at baseline was 3 (1 to 4) points. Respiratory failure HP Respiratory failure MESHD and ARDS developed in 62 (75.6%) and 45 (54.9%) patients, respectively. Median time from symptom onset TRANS to ARDS development was 8 (5 to 11) days. The median time from symptom onset TRANS to the first dose of tocilizumab was 9 (7 to 11) days. Mortality at 7 days was 26.8%. Hazard ratio for mortality was 3.3; 95% CI, 1.3 to 8.5 ( age TRANS adjusted hazard ratio for mortality 2.1; 95% CI, 0.8 to 5.8) if tocilizumab was administered after the onset of ARDS. Conclusion: Time from lung injury MESHD onset to tocilizumab administration may be critical to patient recovery. Our preliminary data could inform bedside decisions until more data from clinical trials becomes available.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.